Epicardial Fat, Visceral Fat and Coronary Atherosclerosis
Association Between Epicardial Fat, Visceral Fat Accumulation & Cardiovascular Atherosclerosis
1 other identifier
observational
110
1 country
1
Brief Summary
Background: Visceral fat is increasingly associated with metabolic syndrome and with fatty liver, a condition carrying a high risk of cardiovascular disease. The independent role of epicardial fat deposition in cardiovascular risk remains unclear.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2011
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 27, 2011
CompletedFirst Posted
Study publicly available on registry
April 29, 2011
CompletedStudy Start
First participant enrolled
July 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2012
CompletedMay 16, 2011
April 1, 2011
7 months
April 27, 2011
May 13, 2011
Conditions
Keywords
Study Arms (3)
patient with liver fat
30 patients with liver fat
excess of visceral fat
50 pts. with excess of visceral fat
control
30 control subjects
Interventions
Eligibility Criteria
50 patients (age 40-70) with excess of visceral fat (obese), 30 patient with liver fat and 30 sexes, age matched individuals will be recruited.
You may qualify if:
- Patients referred to cardiac CT will be the source of recruitment.
- patients with excess of visceral fat,
- patients with liver fat accumulation
- sex-age-matched individual (controls) will be enrolled. All patients will undergo a complete family history, personal clinical history, physical examination and blood sampling for biochemical analysis.
- Informed consent will be obtained from each individual.
You may not qualify if:
- subjects with severe morbid obesity (body mass index \[BMI\] \> 40),
- recent history of acute illness,
- clinical history of ischemic heart disease and cerebrovascular disease,
- typical chest pain,
- previous coronary artery disease,
- conventional coronary angiography, percutaneous interventions, coronary by pass grafting, renal failure, cancer patients,
- subjects who take drugs that induces hepatic steatosis ( corticosteroids, estrogens, methotrexate, amiodarone and others)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ziv Hospitallead
Study Sites (1)
Ziv MC
Safed, 13100, Israel
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nimer Assy, md
Ziv MC
Central Study Contacts
Study Design
- Study Type
- observational
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER GOV
Study Record Dates
First Submitted
April 27, 2011
First Posted
April 29, 2011
Study Start
July 1, 2011
Primary Completion
February 1, 2012
Study Completion
March 1, 2012
Last Updated
May 16, 2011
Record last verified: 2011-04